Newly Listed NewAmsterdam Pharma Touts Encouraging Data From High Cholesterol Treatment

NewAmsterdam Pharma Company N.V. NAMS announced topline results from ROSE2 Phase 2 trial evaluating obicetrapib in combination with ezetimibe as an adjunct to high-intensity statin therapy.
NewAmsterdam is now selecting a formulated fixed-dose combination tablet of obicetrapib plus ezetimibe, a non-statin oral LDL-lowering therapy, to be tested in a definitive bioequivalence and a Phase 3 safety & efficacy trial.
The primary efficacy endpoint for the percent change from Day 1 to Day 84 in LDL-C for the combination treatment group compared to the placebo group was met.
Patients treated with the combination of obicetrapib and ezetimibe achieved a median reduction in LDL-C of 59% compared to patients treated with a placebo, who achieved a median reduction in LDL-C of 6%.
Overall, the obicetrapib combo therapy was well-tolerated, with a safety profile comparable to a placebo.
In November 2022, NewAmsterdam Pharma debuted a public company via a SPAC deal with Frazier Lifesciences Acquisition Corporation.
After the transaction, the company held a cash balance of approximately $490 million, which it believes will be sufficient to fund operations through 2026.
Price Action: NAMS shares are trading lower by 2.25% at $9.99 on the last check Tuesday.